Summary

PROactive, a prospective, multicenter, randomized, doubleblind placebo-controlled parallel-group trial, compared up to 45 mg/day of pioglitazone (PGZ) on top of other medication (optimal treatment of diabetes, dyslipidemia and hypertension) to placebo in 5,238 patients with type 2 diabetes and macrovascular disease. The PROactive study objective was to see if the glucose-lowering agent, already known to have beneficial effects on cardiovascular disease risk factors such as HDL cholesterol, triglycerides, LDL particle size and inflammatory mediators, would reduce total mortality and macrovascular morbidity in these high-risk patients.